Home » Medical Devices » Rapid Influenza Diagnostic Test (RIDT) Market

Rapid Influenza Diagnostic Test (RIDT) Market By End User (Hospitals & Clinics, Laboratories)-Growth, Future Prospects & Competitive Analysis, 2016 – 2030

Summary
Table Of Content

Actionable Insights Delivered – Rapid Influenza Diagnostic Test (RIDT) Market Size

Positioned with a USD 1.2 billion valuation in 2022, the Rapid Influenza Diagnostic Test (RIDT) Market asserted its global eminence. Set to scale to USD 1.99 billion by 2030, the market’s remarkable Compound Annual Growth Rate (CAGR) of 7.5% (2022-2030) underscores its strategic growth trajectory.

Key Highlights of the Report

The global rapid influenza diagnostic test (RIDT) market is segmented by end-user and region. Hospitals & clinics dominated the end-user segment, reflecting their significance in adopting RIDTs for influenza detection. North America is the largest global market for RIDTs, followed by Europe and the Asia-Pacific region.

The rising incidence of influenza, the shift towards point-of-care testing for quick results, ongoing technological advancements improving test accuracy, regulatory approvals ensuring safety and effectiveness, and the impact of the COVID-19 pandemic emphasizing the importance of rapid diagnostic testing are key global market drivers. However, the market also faces certain restraints, such as the potential for false negatives or positives in test results, regulatory challenges & approvals, competition from alternative diagnostic methods, and concerns related to cost-effectiveness.

On the other hand, global rapid influenza diagnostic test (RIDT) market opportunities exist in emerging economies with expanding healthcare infrastructure, development of advanced RIDTs, integration into telemedicine and remote healthcare platforms, strategic collaborations, and expansion into adjacent markets such as infectious disease testing and point-of-care diagnostics.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

What Are The Main Drivers Of The Global Rapid Influenza Diagnostic Test (RIDT) Market?

The growing prevalence of influenza worldwide, the growing demand for quick and accurate diagnostic methods, a shift towards point-of-care testing, technological advancements leading to improved test sensitivity and specificity, and regulatory approvals ensuring the safety and effectiveness of RIDTs are the primary drivers of the global rapid influenza diagnostic test (RIDT) market expansion. Furthermore, the COVID-19 pandemic has emphasized the significance of rapid diagnostic testing, resulting in the adoption RIDTs for distinguishing between influenza and COVID-19 patients, boosting market growth.

What Are The Major Challenges Faced By The Global Rapid Influenza Diagnostic Test (RIDT) Market?

The major challenges faced by the global rapid influenza diagnostic test (RIDT) market include the need for continuous technological advancements to improve test accuracy, the potential for false negatives or positives in test results, the emergence of new strains of influenza that may require updates to test kits, regulatory challenges related to obtaining approvals for new products, and competition from alternative diagnostic methods such as molecular testing. The market also faces challenges related to cost-effectiveness, accessibility in resource-limited settings, and the ongoing impact of the COVID-19 pandemic on healthcare systems and priorities.

What Are The Growth Opportunities In The Global Rapid Influenza Diagnostic Test (RIDT) Market?

The global rapid influenza diagnostic test (RIDT) market presents growth opportunities in the form of increasing demand for RIDTs in emerging economies with expanding healthcare infrastructure, the development of advanced RIDTs with improved sensitivity and specificity, the integration of RIDTs into telemedicine and remote healthcare platforms, and the potential for expansion into adjacent markets such as infectious disease testing and point-of-care diagnostics. Moreover, the growing focus on early and accurate diagnosis and the need for effective influenza surveillance creates avenues for market growth and innovation.

Executive Summary

Overview of the Global Rapid Influenza Diagnostic Test (RIDT) Market

The global rapid influenza diagnostic test (RIDT) market has been experiencing steady growth owing to the increasing prevalence of influenza worldwide. RIDTs are point-of-care testing methods that provide quick results for detecting influenza viruses. They play a crucial role in early and accurate diagnosis, aiding in patient management and containing the spread of the virus. The market encompasses a range of RIDT products developed by different manufacturers, each with its technology, test format, and performance characteristics.

Market Definition

Rapid influenza diagnostic tests (RIDTs) are diagnostic tools designed to detect the presence of influenza viruses in respiratory specimens. These tests, usually within minutes, provide quick results and are commonly used in healthcare settings, clinics, and laboratories. RIDTs are designed to identify specific viral antigens or nucleic acid sequences associated with influenza viruses, allowing healthcare professionals to promptly diagnose and differentiate influenza infections. They offer convenience, accessibility, and reliability, enabling timely interventions and appropriate patient care.

Market Insights

The global demand for rapid influenza diagnostic tests (RIDT) was valued at USD 1.2 Billion in 2022 and is expected to reach USD 1.99 Billion in 2030, growing at a CAGR of 7.5% between 2023 and 2030.
In 2022, hospitals and clinics took the top spot among end-users, with more than 40% of the market share, while laboratories are predicted to increase at the quickest rate.
North America dominated the RIDT market in 2022, accounting for approximately 44% of the market’s revenue worldwide. Increased government surveillance and the existence of significant industry participants are also responsible for this expansion.
India and China are predicted to be the main drivers of Asia Pacific’s strong revenue CAGR over the projection period. The area gains from a sizable patient base, increased governmental coordination, and improvements in the healthcare system.
The development of increasingly sensitive and specialised RIDTs has increased their diagnostic accuracy and dependability as a result of ongoing technical improvements.

Segmentation by End User

Hospitals and clinics dominate the rapid influenza diagnostic test (RIDT) market segment, contributing to over 40% of the market share in terms of value in 2022. The high prevalence of influenza cases and the need for immediate diagnosis in healthcare settings drive the demand for RIDTs in hospitals and clinics.
The laboratories segment is expected to exhibit the fastest CAGR over the projected period. This growth can be due to the increasing outsourcing of diagnostic testing services to laboratories, advancements in laboratory technologies, and the ability of laboratories to handle a large volume of samples efficiently.

Segmentation by Region

North America dominated the global rapid influenza diagnostic test (RIDT) market in 2022, accounting for over 44% of revenue share.
Europe is another prominent global rapid influenza diagnostic test (RIDT) market, contributing substantially to the overall market share.
The Asia-Pacific region is experiencing rapid growth, with a high CAGR in the rapid influenza diagnostic test (RIDT) industry.
The rest of the World, including regions like the Middle East, Latin America, and Africa, is witnessing the rapid adoption of rapid influenza diagnostic test (RIDT) solutions.

The global rapid influenza diagnostic test (RIDT) market is driven by the increasing incidence of influenza, a shift towards point-of-care testing, ongoing technological advancements improving test accuracy, regulatory approvals ensuring safety & effectiveness, and the impact of the COVID-19 pandemic. However, the market also faces restraints such as potential false negatives or positives in test results, regulatory challenges & approvals, and competition from alternative diagnostic methods.

The United States is a key country in the global RIDT market. It has a well-established healthcare infrastructure, advanced diagnostic capabilities, and significant investments in research and development. The country’s high prevalence of influenza cases, especially during flu seasons, drives the demand for rapid diagnostic testing. The presence of major RIDT manufacturers, strong regulatory frameworks, and collaborations between healthcare institutions and manufacturers contribute to market growth. Besides, the U.S. has a proactive approach to public health surveillance, emphasizing the importance of early detection and containment of influenza outbreaks.

China is a major contributor to the RIDT market. The country has large population increases the risk of influenza transmission and fuels the demand for rapid diagnostic tests. The government’s focus on improving healthcare infrastructure, increasing access to healthcare services, and enhancing disease surveillance systems further supports the growth of the RIDT market. China’s robust manufacturing capabilities, technological advancements, and growing investments in biotechnology and healthcare contribute to developing and adopting innovative RIDTs. The country’s expanding middle class and rising healthcare expenditure also drive market growth, making China a key market for RIDT manufacturers.

Increasing Incidence of Influenza

The rising incidence of influenza worldwide is a major driver of the RIDT market. Influenza is a highly contagious respiratory infection, and the demand for rapid and accurate diagnostic tests is increasing to facilitate early detection and appropriate management. The seasonal nature of influenza outbreaks and the potential for pandemics propel the need for effective RIDTs to enable timely diagnosis and containment strategies.

Seasonal influenza causes around 3 – 5 million cases of severe illness worldwide each year, as per World Health Organization (WHO) studies. According to the European Centre for Disease Prevention & Control, influenza infects 10% to 30% of Europe’s population annually. Moreover, around 1.3 million influenza specimens were tested in the United States between October 2020 and July 2021.

Shift toward Point-of-Care Testing

There is a significant shift towards point-of-care testing (POCT) methods, including RIDTs, in the healthcare industry. The convenience and rapid turnaround time of RIDTs allow for quick diagnosis at the patient’s location, enabling immediate clinical decision-making and improving patient outcomes. The growing adoption of POCT and integrating RIDTs into telemedicine and remote healthcare platforms further drive the demand for RIDTs. These developments in the influenza A & B test, which offers molecular flu results in less than 15 minutes, have increased the demand and success rate of the test. Rapid influenza diagnostic testing industry players prioritize R&D activities for producing technologically sophisticated diagnostic tests.

False Negatives or Positives in Test Results

One of the key restraints in the RIDT market is the potential for false negatives or positives in test results. RIDTs may sometimes produce inaccurate results due to test sensitivity and specificity variations. False negatives can lead to delayed diagnosis and inappropriate patient management, while false positives can cause unnecessary anxiety and resource utilization. Ensuring the accuracy and reliability of RIDTs remains a challenge for manufacturers and healthcare providers.

Growing Demand in Emerging Economies

Emerging economies, particularly in Asia-Pacific and Latin America, present significant growth opportunities for the RIDT market. These regions have expanding healthcare infrastructure, a large patient population, and increasing awareness about the importance of early diagnosis. The growing investments in healthcare and the rising demand for improved diagnostic capabilities in these regions create a favorable market environment for RIDTs.

Development of Advanced RIDTs

Technological advancements offer opportunities to develop advanced RIDTs with improved sensitivity, specificity, and accuracy. Innovations in diagnostic platforms, such as molecular-based assays and multiplexed testing, can enhance the performance and diagnostic capabilities of RIDTs. Manufacturers investing in research & development to develop next-generation RIDTs have the potential to gain a competitive advantage and capture a larger market share.

Competitive Landscape

Key Players

The competitive landscape of the global rapid influenza diagnostic test (RIDT) market is characterized by a mix of established players and new entrants striving to gain market share. Some of the major players in the market and their market share are as follows:

Alere Inc
Quidel Corporation
DiaSorin
Meridian Bioscience Inc
SA Scientific Ltd
Becton
Dickinson & Company
Analytik Jena AG
Thermo Fisher Scientific
Roche Diagnostics
Luminex Corporation

These companies focus on R&D operations to introduce technologically advanced and more accurate RIDTs. Strategic collaborations and partnerships with healthcare providers, government agencies, and other stakeholders are common to enhance product reach and distribution.

The market is also witnessing the entry of new players, particularly in emerging economies, intensifying competition. Additionally, marketing initiatives and product launches are used to create brand awareness and gain a competitive edge. Pricing strategies and cost-effectiveness of RIDTs are crucial factors influencing market positioning, with companies striving to offer affordable and reliable diagnostic solutions to meet the growing demand in the global market.

For instance, Pfizer stated in September 2022 that it would begin a phase 3 clinical trial of the influenza vaccine. The company used mRNA technology to discover more about more effective vaccines that help lower flu-related hospitalization and death rates. Several corporations, including Moderna, have created flu vaccines to gain a competitive advantage.

Similarly, BD (Becton, Dickinson, and Company) announced in June 2022 that the BD MAX Respiratory Viral Panel (RVP), a new molecular diagnostic combination test for Influenza A + B, SARS-CoV-2, and Respiratory Syncytial Virus (RSV), had been CE marked by IVD Directive 98/79/EC.

DiaSorin SpA reported the acquisition of Luminex Corporation, a firm that develops diagnostic solutions for infectious diseases, in April 2021. This acquisition broadened its diagnostic range in the United States, including influenza diagnostic products. This strategic decision benefited the organization in expanding its customer base and strengthening its industry presence.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Summary of Key Findings

The global RIDT market has been expanding continuously, owing to the rising prevalence of influenza and the demand for quick and accurate diagnostic techniques.
Market segmented by end-user and region.
In 2022, Hospitals & clinics dominated the end-user segment, accounting for over 40% of the market share.
North America holds the largest market share, followed by Europe, with the Asia-Pacific region exhibiting high growth potential.
The market faces challenges such as the need for continuous technological advancements, the potential for false negatives or positives in test results, regulatory hurdles, and competition from alternative diagnostic methods.
The COVID-19 pandemic has highlighted the importance of rapid diagnostic testing, including RIDTs, for differentiating between influenza and COVID-19 cases.
Point-of-care testing (POCT) is gaining prominence, leading to increased adoption of RIDTs in various healthcare settings.

Future Outlook

RIDTs play a key role in public health strategies for influenza surveillance, outbreak management, and monitoring of vaccine effectiveness.
Emerging economies and the development of advanced RIDTs present growth opportunities in the market.
RIDTs are increasingly being adopted in non-traditional settings, such as pharmacies, workplaces, and community healthcare centers, to enhance access to influenza testing.

Segmentation

By End User
- Hospitals & Clinics
- Laboratories
- Others
By Region

North America
- The U.S.
- Canada
- Mexico
Europe
- Germany
- France
- The U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Data Modelling
1.3.2.1. Company Share Analysis Model
1.3.2.2. Revenue-Based Modelling
1.3.3. Phase III – Primary Research
1.3.4. Research Limitations
1.3.5. Assumptions
1.4. Market Introduction
1.5. Market Research Scope

2. Executive Summary
2.1. Market Snapshot: Global Rapid Influenza Diagnostic Test (RIDT) Market
2.2. Global Rapid Influenza Diagnostic Test (RIDT) Market, By End User
2.3. Global Rapid Influenza Diagnostic Test (RIDT) Market, By Region

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Rapid Influenza Diagnostic Test (RIDT) Market Value, 2017-2030, (US$ Bn)
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.2. Market Restraints
3.2.3. Market Opportunities
3.2.4. Major Industry Challenges
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. End User
3.5.2. Geography

4. Premium Insights
4.1. STAR (Situation, Task, Action, Results) Analysis
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers/Consumers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitute Types
4.2.5. Intensity of Competitive Rivalry
4.3. Key Market Trends
4.3.1. Demand Side Trends
4.3.2. Supply Side Trends
4.4. Value Chain Analysis
4.5. Technology Analysis
4.6. Analysis and Recommendations
4.7. Marketing Strategy Analysis
4.7.1. Direct Marketing
4.7.2. Indirect Marketing
4.7.3. Marketing Channel Development Trend

5. Market Positioning of Key Players, 2022
5.1. Company Market Share of Key Players, 2022
5.2. Competitive Benchmarking
5.3. Market Positioning of Key Vendors
5.4. Geographical Presence Analysis
5.5. Major Strategies Adopted by Key Players
5.5.1. Key Strategies Analysis
5.5.2. Mergers and Acquisitions
5.5.3. Partnerships
5.5.4. Product Launch
5.5.5. Geographical Expansion
5.5.6. Others

6. Economic Impact Analysis
6.1. Recession Impact
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Latin America
6.1.5. Middle East and Africa
6.2. Ukraine-Russia War Impact
6.2.1. North America
6.2.2. Europe
6.2.3. Asia Pacific
6.2.4. Latin America
6.2.5. Middle East and Africa
6.3. COVID-19 Impact Analysis
6.3.1. North America
6.3.2. Europe
6.3.3. Asia Pacific
6.3.4. Latin America
6.3.5. Middle East and Africa

7. Global Rapid Influenza Diagnostic Test (RIDT) Market, By End User
7.1. Global Rapid Influenza Diagnostic Test (RIDT) Market Overview, by End User
7.1.1. Global Rapid Influenza Diagnostic Test (RIDT) Market, By End User, 2022 vs 2030 (in %)
7.2. Hospitals & Clinics
7.2.1. Global Rapid Influenza Diagnostic Test (RIDT) Market, By Region, 2017-2030 (US$ Bn)
7.3. Laboratories
7.3.1. Global Rapid Influenza Diagnostic Test (RIDT) Market, By Region, 2017-2030 (US$ Bn)
7.4. Others
7.4.1. Global Rapid Influenza Diagnostic Test (RIDT) Market, By Region, 2017-2030 (US$ Bn)

8. Global Rapid Influenza Diagnostic Test (RIDT) Market, By Region
8.1. Global Rapid Influenza Diagnostic Test (RIDT) Market Overview, by Region
8.1.1. Global Rapid Influenza Diagnostic Test (RIDT) Market, By Region, 2022 vs 2030 (in%)
8.2. End User
8.2.1. Global Rapid Influenza Diagnostic Test (RIDT) Market, By End User, 2017-2030 (US$ Bn)

9. North America Rapid Influenza Diagnostic Test (RIDT) Market Analysis
9.1. North America Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2017-2030(US$ Bn)
9.1.1. Overview
9.1.2. SRC Analysis
9.2. North America Rapid Influenza Diagnostic Test (RIDT) Market, by Country, 2017-2030 (US$ Bn)
9.2.1. North America Rapid Influenza Diagnostic Test (RIDT) Market, by Country, 2022 Vs 2030 (in%)
9.2.2. U.S.
9.2.2.1. U.S. Rapid Influenza Diagnostic Test (RIDT) Market Estimates and Forecast, 2017-2030 (US$ Bn)
9.2.2.2. U.S. Rapid Influenza Diagnostic Test (RIDT), By End User, 2017-2030 (US$ Bn)
9.2.3. Canada
9.2.3.1. Canada Rapid Influenza Diagnostic Test (RIDT) Market Estimates and Forecast, 2017-2030 (US$ Bn)
9.2.3.2. Canada Rapid Influenza Diagnostic Test (RIDT), By End User, 2017-2030 (US$ Bn)
9.2.4. Mexico
9.2.4.1. Mexico Rapid Influenza Diagnostic Test (RIDT) Market Estimates and Forecast, 2017-2030 (US$ Bn)
9.2.4.2. Mexico Rapid Influenza Diagnostic Test (RIDT), By End User, 2017-2030 (US$ Bn)

10. Europe Rapid Influenza Diagnostic Test (RIDT) Market Analysis
10.1. Europe Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2017-2030(US$ Bn)
10.1.1. Overview
10.1.2. SRC Analysis
10.2. Europe Rapid Influenza Diagnostic Test (RIDT) Market, by Country, 2017-2030 (US$ Bn)
10.2.1. Europe Rapid Influenza Diagnostic Test (RIDT) Market, by Country, 2022 Vs 2030 (in%)
10.2.2. Germany
10.2.2.1. Germany Rapid Influenza Diagnostic Test (RIDT) Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.2.2.2. Germany Rapid Influenza Diagnostic Test (RIDT), By End User, 2017-2030 (US$ Bn)
10.2.3. France
10.2.3.1. France Rapid Influenza Diagnostic Test (RIDT) Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.2.3.2. France Rapid Influenza Diagnostic Test (RIDT), By End User, 2017-2030 (US$ Bn)
10.2.4. UK
10.2.4.1. UK Rapid Influenza Diagnostic Test (RIDT) Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.2.4.2. UK Rapid Influenza Diagnostic Test (RIDT), By End User, 2017-2030 (US$ Bn)
10.2.5. Italy
10.2.5.1. Italy Rapid Influenza Diagnostic Test (RIDT) Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.2.5.2. Italy Rapid Influenza Diagnostic Test (RIDT), By End User, 2017-2030 (US$ Bn)
10.2.6. Spain
10.2.6.1. Spain Rapid Influenza Diagnostic Test (RIDT) Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.2.6.2. Spain Rapid Influenza Diagnostic Test (RIDT), By End User, 2017-2030 (US$ Bn)
10.2.7. Rest of Europe
10.2.7.1. Rest of Europe Rapid Influenza Diagnostic Test (RIDT) Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.2.7.2. Rest of Europe Rapid Influenza Diagnostic Test (RIDT), By End User, 2017-2030 (US$ Bn)

11. Asia Pacific Rapid Influenza Diagnostic Test (RIDT) Market Analysis
11.1. Asia Pacific Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2017-2030(US$ Bn)
11.1.1. Overview
11.1.2. SRC Analysis
11.2. Asia Pacific Rapid Influenza Diagnostic Test (RIDT) Market, by Country, 2017-2030 (US$ Bn)
11.2.1. Asia Pacific Rapid Influenza Diagnostic Test (RIDT) Market, by Country, 2022 Vs 2030 (in%)
11.2.2. China
11.2.2.1. China Rapid Influenza Diagnostic Test (RIDT) Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.2.2.2. China Rapid Influenza Diagnostic Test (RIDT), By End User, 2017-2030 (US$ Bn)
11.2.3. Japan
11.2.3.1. Japan Rapid Influenza Diagnostic Test (RIDT) Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.2.3.2. Japan Rapid Influenza Diagnostic Test (RIDT), By End User, 2017-2030 (US$ Bn)
11.2.4. India
11.2.4.1. India Rapid Influenza Diagnostic Test (RIDT) Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.2.4.2. India Rapid Influenza Diagnostic Test (RIDT), By End User, 2017-2030 (US$ Bn)
11.2.5. South Korea
11.2.5.1. South Korea Rapid Influenza Diagnostic Test (RIDT) Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.2.5.2. South Korea Rapid Influenza Diagnostic Test (RIDT), By End User, 2017-2030 (US$ Bn)
11.2.6. South-East Asia
11.2.6.1. South-East Asia Rapid Influenza Diagnostic Test (RIDT) Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.2.6.2. South-East Asia Rapid Influenza Diagnostic Test (RIDT), By End User, 2017-2030 (US$ Bn)
11.2.7. Rest of Asia Pacific
11.2.7.1. Rest of Asia Pacific Rapid Influenza Diagnostic Test (RIDT) Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.2.7.2. Rest of Asia Pacific Rapid Influenza Diagnostic Test (RIDT), By End User, 2017-2030 (US$ Bn)

12. Latin America Rapid Influenza Diagnostic Test (RIDT) Market Analysis
12.1. Latin America Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2017-2030(US$ Bn)
12.1.1. Overview
12.1.2. SRC Analysis
12.2. Latin America Rapid Influenza Diagnostic Test (RIDT) Market, by Country, 2017-2030 (US$ Bn)
12.2.1. Latin America Rapid Influenza Diagnostic Test (RIDT) Market, by Country, 2022 Vs 2030 (in%)
12.2.2. Brazil
12.2.2.1. Brazil Rapid Influenza Diagnostic Test (RIDT) Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.2.2.2. Brazil Rapid Influenza Diagnostic Test (RIDT), By End User, 2017-2030 (US$ Bn)
12.2.3. Argentina
12.2.3.1. Argentina Rapid Influenza Diagnostic Test (RIDT) Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.2.3.2. Argentina Rapid Influenza Diagnostic Test (RIDT), By End User, 2017-2030 (US$ Bn)
12.2.4. Rest of Latin America
12.2.4.1. Rest of Latin America Rapid Influenza Diagnostic Test (RIDT) Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.2.4.2. Rest of Latin America Rapid Influenza Diagnostic Test (RIDT), By End User, 2017-2030 (US$ Bn)

13. Middle East and Africa Rapid Influenza Diagnostic Test (RIDT) Market Analysis
13.1. Middle East and Africa Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2017-2030(US$ Bn)
13.1.1. Overview
13.1.2. SRC Analysis
13.2. Middle East and Africa Rapid Influenza Diagnostic Test (RIDT) Market, by Country, 2017-2030 (US$ Bn)
13.2.1. Middle East and Africa Rapid Influenza Diagnostic Test (RIDT) Market, by Country, 2022 Vs 2030 (in%)
13.2.2. GCC Countries
13.2.2.1. GCC Countries Rapid Influenza Diagnostic Test (RIDT) Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.2.2.2. GCC Countries Rapid Influenza Diagnostic Test (RIDT), By End User, 2017-2030 (US$ Bn)
13.2.3. South Africa
13.2.3.1. South Africa Rapid Influenza Diagnostic Test (RIDT) Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.2.3.2. South Africa Rapid Influenza Diagnostic Test (RIDT), By End User, 2017-2030 (US$ Bn)
13.2.4. Rest of Middle East and Africa
13.2.4.1. Rest of Middle East and Africa Rapid Influenza Diagnostic Test (RIDT) Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.2.4.2. Rest of Middle East and Africa Rapid Influenza Diagnostic Test (RIDT), By End User, 2017-2030 (US$ Bn)

14. Company Profiles
14.1. Alere Inc
14.1.1. Company Overview
14.1.2. Products/Services Portfolio
14.1.3. Geographical Presence
14.1.4. Financial Summary
14.1.4.1. Market Revenue and Net Profit (2019-2022)
14.1.4.2. Business Segment Revenue Analysis
14.1.4.3. Geographical Revenue Analysis
14.2. Quidel Corporation
14.3. DiaSorin
14.4. Meridian Bioscience Inc
14.5. SA Scientific Ltd
14.6. Becton, Dickinson & Company
14.7. Analytik Jena AG
14.8. Thermo Fisher Scientific
14.9. Roche Diagnostics
14.10. Luminex Corporation

List of Figures
FIG. 1 Global Rapid Influenza Diagnostic Test (RIDT) Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom Up Approach
FIG. 3 Global Rapid Influenza Diagnostic Test (RIDT) Market Segmentation
FIG. 4 Global Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2022 (US$ Bn)
FIG. 5 Global Rapid Influenza Diagnostic Test (RIDT) Market, by Geography, 2022 (US$ Bn)
FIG. 6 Attractive Investment Proposition, by End User, 2022
FIG. 7 Attractive Investment Proposition, by Geography, 2022
FIG. 8 Global Market Share Analysis of Key Rapid Influenza Diagnostic Test (RIDT) Market Manufacturers, 2022
FIG. 9 Global Market Positioning of Key Rapid Influenza Diagnostic Test (RIDT) Market Manufacturers, 2022
FIG. 10 Global Rapid Influenza Diagnostic Test (RIDT) Market Value Contribution, By End User, 2022 & 2030 (Value %)
FIG. 11 Global Rapid Influenza Diagnostic Test (RIDT) Market, by Hospitals & Clinics, 2017-2030 (US$ Bn)
FIG. 12 Global Rapid Influenza Diagnostic Test (RIDT) Market, by Laboratories, 2017-2030 (US$ Bn)
FIG. 13 Global Rapid Influenza Diagnostic Test (RIDT) Market, by Others, 2017-2030 (US$ Bn)
FIG. 14 North America Rapid Influenza Diagnostic Test (RIDT) Market, 2017-2030 (US$ Bn)
FIG. 15 U.S. Rapid Influenza Diagnostic Test (RIDT) Market, 2017-2030 (US$ Bn)
FIG. 16 Canada Rapid Influenza Diagnostic Test (RIDT) Market, 2017-2030 (US$ Bn)
FIG. 17 Europe Rapid Influenza Diagnostic Test (RIDT) Market, 2017-2030 (US$ Bn)
FIG. 18 Germany Rapid Influenza Diagnostic Test (RIDT) Market, 2017-2030 (US$ Bn)
FIG. 19 France Rapid Influenza Diagnostic Test (RIDT) Market, 2017-2030 (US$ Bn)
FIG. 20 U.K. Rapid Influenza Diagnostic Test (RIDT) Market, 2017-2030 (US$ Bn)
FIG. 21 Italy Rapid Influenza Diagnostic Test (RIDT) Market, 2017-2030 (US$ Bn)
FIG. 22 Spain Rapid Influenza Diagnostic Test (RIDT) Market, 2017-2030 (US$ Bn)
FIG. 23 Rest of Europe Rapid Influenza Diagnostic Test (RIDT) Market, 2017-2030 (US$ Bn)
FIG. 24 Asia Pacific Rapid Influenza Diagnostic Test (RIDT) Market, 2017-2030 (US$ Bn)
FIG. 25 China Rapid Influenza Diagnostic Test (RIDT) Market, 2017-2030 (US$ Bn)
FIG. 26 Japan Rapid Influenza Diagnostic Test (RIDT) Market, 2017-2030 (US$ Bn)
FIG. 27 India Rapid Influenza Diagnostic Test (RIDT) Market, 2017-2030 (US$ Bn)
FIG. 28 South Korea Rapid Influenza Diagnostic Test (RIDT) Market, 2017-2030 (US$ Bn)
FIG. 29 South-East Asia Rapid Influenza Diagnostic Test (RIDT) Market, 2017-2030 (US$ Bn)
FIG. 30 Rest of Asia Pacific Rapid Influenza Diagnostic Test (RIDT) Market, 2017-2030 (US$ Bn)
FIG. 31 Latin America Rapid Influenza Diagnostic Test (RIDT) Market, 2017-2030 (US$ Bn)
FIG. 32 Brazil Rapid Influenza Diagnostic Test (RIDT) Market, 2017-2030 (US$ Bn)
FIG. 33 Mexico Rapid Influenza Diagnostic Test (RIDT) Market, 2017-2030 (US$ Bn)
FIG. 34 Rest of Latin America Rapid Influenza Diagnostic Test (RIDT) Market, 2017-2030 (US$ Bn)
FIG. 35 Middle East & Africa Rapid Influenza Diagnostic Test (RIDT) Market, 2017-2030 (US$ Bn)
FIG. 36 GCC Countries Rapid Influenza Diagnostic Test (RIDT) Market, 2017-2030 (US$ Bn)
FIG. 37 South Africa Rapid Influenza Diagnostic Test (RIDT) Market, 2017-2030 (US$ Bn)
FIG. 38 Rest of Middle East and Africa Rapid Influenza Diagnostic Test (RIDT) Market, 2017-2030 (US$ Bn)

List of Tables
TABLE 1 Market Snapshot: Global Rapid Influenza Diagnostic Test (RIDT) Market
TABLE 2 Global Rapid Influenza Diagnostic Test (RIDT) Market: Market Drivers Impact Analysis
TABLE 3 Global Rapid Influenza Diagnostic Test (RIDT) Market: Market Restraints Impact Analysis
TABLE 4 Global Rapid Influenza Diagnostic Test (RIDT) Market, by Competitive Benchmarking, 2022
TABLE 5 Global Rapid Influenza Diagnostic Test (RIDT) Market, by Geographical Presence Analysis, 2022
TABLE 6 Global Rapid Influenza Diagnostic Test (RIDT) Market, by Key Strategies Analysis, 2022
TABLE 7 Global Rapid Influenza Diagnostic Test (RIDT) Market, by Hospitals & Clinics, By Region, 2017-2022 (US$ Bn)
TABLE 8 Global Rapid Influenza Diagnostic Test (RIDT) Market, by Hospitals & Clinics, By Region, 2023-2030 (US$ Bn)
TABLE 9 Global Rapid Influenza Diagnostic Test (RIDT) Market, by Laboratories, By Region, 2017-2022 (US$ Bn)
TABLE 10 Global Rapid Influenza Diagnostic Test (RIDT) Market, by Laboratories, By Region, 2023-2030 (US$ Bn)
TABLE 11 Global Rapid Influenza Diagnostic Test (RIDT) Market, by Others, By Region, 2017-2022 (US$ Bn)
TABLE 12 Global Rapid Influenza Diagnostic Test (RIDT) Market, by Others, By Region, 2023-2030 (US$ Bn)
TABLE 13 Global Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2017-2022 (US$ Bn)
TABLE 14 Global Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2023-2030 (US$ Bn)
TABLE 15 Global Rapid Influenza Diagnostic Test (RIDT) Market, by Region, 2017-2022 (US$ Bn)
TABLE 16 Global Rapid Influenza Diagnostic Test (RIDT) Market, by Region, 2023-2030 (US$ Bn)
TABLE 17 North America Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2017-2022 (US$ Bn)
TABLE 18 North America Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2023-2030 (US$ Bn)
TABLE 19 North America Rapid Influenza Diagnostic Test (RIDT) Market, by Country, 2017-2022 (US$ Bn)
TABLE 20 North America Rapid Influenza Diagnostic Test (RIDT) Market, by Country, 2023-2030 (US$ Bn)
TABLE 21 United States Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2017-2022 (US$ Bn)
TABLE 22 United States Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2023-2030 (US$ Bn)
TABLE 23 Canada Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2017-2022 (US$ Bn)
TABLE 24 Canada Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2023-2030 (US$ Bn)
TABLE 25 Mexico Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2017-2022 (US$ Bn)
TABLE 26 Mexico Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2023-2030 (US$ Bn)
TABLE 27 Europe Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2017-2022 (US$ Bn)
TABLE 28 Europe Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2023-2030 (US$ Bn)
TABLE 29 Europe Rapid Influenza Diagnostic Test (RIDT) Market, by Country, 2017-2022 (US$ Bn)
TABLE 30 Europe Rapid Influenza Diagnostic Test (RIDT) Market, by Country, 2023-2030 (US$ Bn)
TABLE 31 Germany Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2017-2022 (US$ Bn)
TABLE 32 Germany Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2023-2030 (US$ Bn)
TABLE 33 France Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2017-2022 (US$ Bn)
TABLE 34 France Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2023-2030 (US$ Bn)
TABLE 35 United Kingdom Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2017-2022 (US$ Bn)
TABLE 36 United Kingdom Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2023-2030 (US$ Bn)
TABLE 37 Italy Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2017-2022 (US$ Bn)
TABLE 38 Italy Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2023-2030 (US$ Bn)
TABLE 39 Spain Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2017-2022 (US$ Bn)
TABLE 40 Spain Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2023-2030 (US$ Bn)
TABLE 41 Rest of Europe Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2017-2022 (US$ Bn)
TABLE 42 Rest of Europe Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2023-2030 (US$ Bn)
TABLE 43 Asia Pacific Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2017-2022 (US$ Bn)
TABLE 44 Asia Pacific Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2023-2030 (US$ Bn)
TABLE 45 China Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2017-2022 (US$ Bn)
TABLE 46 China Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2023-2030 (US$ Bn)
TABLE 47 Japan Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2017-2022 (US$ Bn)
TABLE 48 Japan Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2023-2030 (US$ Bn)
TABLE 49 India Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2017-2022 (US$ Bn)
TABLE 50 India Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2023-2030 (US$ Bn)
TABLE 51 South Korea Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2017-2022 (US$ Bn)
TABLE 52 South Korea Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2023-2030 (US$ Bn)
TABLE 53 South-East Asia Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2017-2022 (US$ Bn)
TABLE 54 South-East Asia Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2023-2030 (US$ Bn)
TABLE 55 Rest of Asia Pacific Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2017-2022 (US$ Bn)
TABLE 56 Rest of Asia Pacific Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2023-2030 (US$ Bn)
TABLE 57 Latin America Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2017-2022 (US$ Bn)
TABLE 58 Latin America Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2023-2030 (US$ Bn)
TABLE 59 Brazil Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2017-2022 (US$ Bn)
TABLE 60 Brazil Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2023-2030 (US$ Bn)
TABLE 61 Argentina Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2017-2022 (US$ Bn)
TABLE 62 Argentina Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2023-2030 (US$ Bn)
TABLE 63 Rest of Latin America Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2017-2022 (US$ Bn)
TABLE 64 Rest of Latin America Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2023-2030 (US$ Bn)
TABLE 65 Middle East and Africa Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2017-2022 (US$ Bn)
TABLE 66 Middle East and Africa Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2023-2030 (US$ Bn)
TABLE 67 GCC Countries Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2017-2022 (US$ Bn)
TABLE 68 GCC Countries Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2023-2030 (US$ Bn)
TABLE 69 South Africa Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2017-2022 (US$ Bn)
TABLE 70 South Africa Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2023-2030 (US$ Bn)
TABLE 71 Rest of Middle East and Africa Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2017-2022 (US$ Bn)
TABLE 72 Rest of Middle East and Africa Rapid Influenza Diagnostic Test (RIDT) Market, by End User, 2023-2030 (US$ Bn)

Frequently Asked Question

What is the current size of the global rapid influenza diagnostic test (RIDT) market?

The global rapid influenza diagnostic test (RIDT) market was valued at USD 1.2 Billion in 2022.

What is the expected growth rate of the rapid influenza diagnostic test (RIDT) market between 2023 and 2030?

The rapid influenza diagnostic test (RIDT) market is expected to grow at a CAGR of 7.5% between 2023 and 2030, reaching USD 1.99 Billion in 2030.

Which segment is leading the market share in terms of end users?

Hospitals & clinics are the leading segment by end-user, holding over 40% share in terms of value in 2022.

Which end-user segment will post the highest CAGR in the forecast period?

The laboratories segment will post the highest CAGR in the projected period.

Which region is fueling the growth of the rapid influenza diagnostic test (RIDT) industry?

Asia Pacific is fueling the rapid growth of the rapid influenza diagnostic test (RIDT) industry, with an over one-third share in 2022.

Who are the major global rapid influenza diagnostic test (RIDT) market players?

The top market players are Alere Inc, DiaSorin, Roche Diagnostics, and SA Scientific Ltd. Other major players include Quidel Corporation, Meridian Bioscience Inc, BD, Thermo Fisher Scientific, and Luminex Corporation.

What are the major market drivers of the rapid influenza diagnostic test (RIDT) industry?

The main market drivers are the rising prevalence of influenza, the shift towards point-of-care testing, technological improvements, rising regulatory approvals, and the impact of the COVID-19 pandemic.

What are the major market restraints of the rapid influenza diagnostic test (RIDT) industry?

The major market restraints are the potential for false negatives or positives in test results, regulatory challenges and approvals, competition from alternative diagnostic methods, and cost-effectiveness concerns.

What are the major market opportunities of the rapid influenza diagnostic test (RIDT) industry?

The major market opportunities of the rapid influenza diagnostic test (RIDT) industry lie in emerging economies with expanding healthcare infrastructure, the development of advanced RIDTs, integration into telemedicine and remote healthcare platforms, strategic collaborations, and expansion into adjacent markets such as infectious disease testing and point-of-care diagnostics.

Purchase Options

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –